Gilead Sciences has agreed to acquire MYR Pharmaceuticals, a German biotechnology company focused on the development and commercialisation of therapeutics for the treatment of chronic hepatitis delta virus (HDV). The deal, which is worth up to US$1.76 B (€1.45 B), gives Gilead access to Hepcludex™ (bulevirtide) – the first, and currently the only, medicine conditionally approved for HDV by the EMA. MYR plans to file a regulatory submission for accelerated approval in the US in the second half of 2021 based on data from an ongoing Phase III study.